JAK Inhibitors Pipeline Outlook Report 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future Landscape
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the JAK Inhibitors Treatment Landscape. Click here to read more @ JAK Inhibitors Pipeline Outlook
Key Takeaways from the JAK Inhibitors Pipeline Report
In June 2025, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announced a study has a total sample size of 78 participants. Of that 78, 52 participants will receive active treatment, and a total of 26 participants will receive placebo. Participants will receive 12 months of active treatment with abrocitinib, ritlecitinib, or placebo with up to 12 months of additional follow-up. During the study, participants will undergo frequent assessments of their insulin production, immunologic status, overall health and well-being and diabetes care.
DelveInsight's JAK Inhibitors pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for JAK Inhibitors treatment.
The leading JAK Inhibitors Companies such as Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis Biotherapeutics/Reistone Biopharma and others.
Promising JAK Inhibitors Pipeline Therapies such as Abrocitinib 200 MG Oral Tablet, Ritlecitinib, GSK3196165 (Otilimab), Sarilumab, Ruxolitinib 0.15% Cream QD and others.
Stay informed about the cutting-edge advancements in JAK Inhibitors Treatments. Download for updates and be a part of the revolution in Immunological and Autoimmune Disorders care @ JAK Inhibitors Clinical Trials Assessment
JAK Inhibitors Emerging Drugs Profile
Povorcitinib: Incyte Corporation
Povorcitinib (INCB054707) is an oral small-molecule JAK1 inhibitor. The chemical structure for povorcitinib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as a Janus kinase inhibitor and anti-inflammatory agent. The drug is also being evaluated in Phase II clinical trials for Prurigo Nodularis, and others. Currently, the drug is in Phase III stage of its development for the treatment of Hidradenitis suppurativa, vitiligo.
CPL409116: Celon Pharma
CPL 409116 is the first in class dual JAK/ROCK inhibitor in clinical development and is designed to generate anti-inflammatory and anti-fibrotic effects in selected autoimmune diseases. CPL'116 was administered orally in single ascending doses in healthy volunteers in order to assess safety and pharmacokinetic parameters (PK). No adverse events associated with administration of the investigational drug were observed, and the trial met its primary endpoint. Currently the drug is in Phase II stage of development for autoimmune indications including in patients with rheumatoid arthritis with coexisting interstitial lung disease.
ATI-2138: Aclaris Therapeutics
ATI-2138 is an investigational oral covalent ITK/JAK3 inhibitor that is being developed as a potential therapeutic option across a variety of T cell-mediated diseases. ITK is a T cell receptor activated kinase involved in driving T cell effector functions while JAK3 is a non-receptor tyrosine kinase responsible for the signal transduction of common gamma receptor cytokines, IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. In blocking both T cell receptor function and cytokine signaling, ATI-2138 has potential utility in T cell driven diseases. ATI-2138 is currently in clinical development and its safety and efficacy has not been evaluated by regulatory authorities.
SDC 1802: Sareum
SDC-1802 is an investigational Sareum's TYK2/JAK1 preclinical development candidate molecule that demonstrates high selectivity for TYK2 and JAK1 kinases (particularly over related JAK2 and JAK3). SDC-1802 shows compelling efficacy in blocking cancer cell proliferation in cellular and disease models of T-cell acute lymphoblastic leukaemia (T-ALL) and B-cell lymphoma, the potential for once-daily oral dosing and a good early safety profile. Sareum is progressing SDC-1802 through preclinical development and pending satisfactory progress, into human clinical trials. SDC-1802 has the potential to act as a back-up molecule for these autoimmune indications. Currently, the drug is in Preclinical stage of its development for the treatment of cancer.
The JAK Inhibitors pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of JAK Inhibitors with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for JAK Inhibitors Treatment.
JAK Inhibitors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
JAK Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the JAK Inhibitors market.
Get a detailed analysis of the latest innovations in the JAK Inhibitors pipeline. Explore DelveInsight's expert-driven report today! @ JAK Inhibitors Unmet Needs
JAK Inhibitors Companies
Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis Biotherapeutics/Reistone Biopharma and others.
Janus Kinase (JAK) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
JAK Inhibitors Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Discover the latest advancements in JAK Inhibitors Treatment by visiting our website. Stay informed about how we're transforming the future of Immunological and Autoimmune Disorders @ JAK Inhibitors Market Drivers and Barriers, and Future Perspectives
Scope of the JAK Inhibitors Pipeline Report
Coverage- Global
JAK Inhibitors Companies- Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis Biotherapeutics/Reistone Biopharma and others.
JAK Inhibitors Pipeline Therapies- Abrocitinib 200 MG Oral Tablet, Ritlecitinib, GSK3196165 (Otilimab), Sarilumab, Ruxolitinib 0.15% Cream QD and others.
JAK Inhibitors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
JAK Inhibitors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of JAK Inhibitors Pipeline on our website @ JAK Inhibitors Emerging Drugs and Companies
Table of Contents
Introduction
Executive Summary
Janus Kinase (JAK) Inhibitor: Overview
Pipeline Therapeutics
Therapeutic Assessment
Janus Kinase (JAK) Inhibitor– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Povorcitinib: Incyte Corporation
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
CPL409116: Celon Pharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ATI-2138: Aclaris Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
SDC 1802: Sareum
Drug profiles in the detailed report…..
Inactive Products
Janus Kinase (JAK) Inhibitor Key Companies
Janus Kinase (JAK) Inhibitor Key Products
Janus Kinase (JAK) Inhibitor- Unmet Needs
Janus Kinase (JAK) Inhibitor- Market Drivers and Barriers
Janus Kinase (JAK) Inhibitor- Future Perspectives and Conclusion
Janus Kinase (JAK) Inhibitor Analyst Views
Janus Kinase (JAK) Inhibitor Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
8 hours ago
- Globe and Mail
Hemophilia Pipeline Outlook Report 2025: Key 80+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Hemophilia Pipeline Insight, 2025,' report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Hemophilia Pipeline Outlook Report Key Takeaways from the Hemophilia Pipeline Report In July 2025, Novo Nordisk A/S announced a study is looking at how safe it is to switch from emicizumab to Mim8, in people with haemophilia A. Mim8 is a new medicine that is used to prevent bleeding episodes in people with haemophilia A. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). Mim8 will be injected under the skin using a pen-injector either once every week, once every two weeks or once every month. The participants will be trained in using the pen injector. In July 2025, Pfizer announced a study to establish baseline prospective efficacy data of current FIX prophylaxis replacement therapy in the usual care setting of hemophilia B subjects, who are negative for nAb to AAV-Spark100, prior to the Phase 3 gene therapy study. In July 2025, Regeneron Pharmaceuticals announced a study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B. This study is researching an experimental gene insertion therapy (the adding of a gene into your DNA) called REGV131-LNP1265, also called the "study drug". Gene insertion therapy aims to teach the body how to produce clotting factor long-term, without the need for factor replacement therapy. DelveInsight's Hemophilia pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Hemophilia treatment. The leading Hemophilia Companies such as Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others. Promising Hemophilia Pipeline Therapies such as NNC0365-3769 (Mim8) PPX, Mim8, STSP-0601 for Injection, Fitusiran, Marstacimab, Fitusiran, BPA prophylaxis, Concizumab, PF-06741086 and others. Discover how the Hemophilia treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Hemophilia Clinical Trials and Studies Hemophilia Emerging Drugs Profile SerpinPC: Centessa Pharmaceuticals SerpinPC, a specific inhibitor of activated protein C (APC), for the treatment of hemophilia A and hemophilia B. SerpinPC has been observed to be well-tolerated in the clinical setting, associated with promising reductions in bleeding rates, and has PK suitable for infrequent subcutaneous dosing without the need for factor replacement. SerpinPC has human genetic target validation and established proof of concept Phase 2a clinical data. Fitusiran: Alnylam Pharmaceuticals Fitusiran (ALN-AT3) is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT) in development for the treatment of hemophilia and rare bleeding disorders (RBDs) by their collaborators at Sanofi Genzyme. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Hemophilia. ASC 618: ASC Therapeutics ASC618 is an AAV8-based gene therapy for the treatment of hemophilia A, affecting approximately 1 of every 5000 live-born males. ASC618 incorporates a novel liver-specific promoter and a bioengineered, codon-optimized B domain-deleted FVIII variant; in preclinical studies, ASC618 exhibits at least a 10-fold increase in the biosynthesis and secretion of FVIII compared with native human FVIII bioengineered gene constructs. ASC618 has the potential to increase durability of clotting factor biosynthesis and secretion by minimizing cellular stress and induction of the unfolded protein response, which may lead to diminished FVIII production from liver cells. ASC Therapeutics will conduct a phase 1/2 clinical trial to evaluate the safety, tolerability, and preliminary efficacy of ASC618. The program received IND clearance from the U.S. Food and Drug Administration. The Hemophilia Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Hemophilia with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia Treatment. Hemophilia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Hemophilia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia market. Get a detailed analysis of the latest innovations in the Hemophilia Pipeline. Explore DelveInsight's expert-driven report today! @ Hemophilia Unmet Needs Hemophilia Companies Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others. Hemophilia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intra-articular Intraocular Intrathecal Intravenous Ophthalmic Oral Parenteral Subcutaneous Topical Transdermal Products have been categorized under various Molecule types such as Oligonucleotide Peptide Small molecule Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key Hemophilia Developments @ Hemophilia Market Drivers and Barriers, and Future Perspectives Scope of the Hemophilia Pipeline Report Coverage- Global Hemophilia Companies- Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others. Hemophilia Pipeline Therapies- NNC0365-3769 (Mim8) PPX, Mim8, STSP-0601 for Injection, Fitusiran, Marstacimab, Fitusiran, BPA prophylaxis, Concizumab, PF-06741086 and others. Hemophilia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Hemophilia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Hemophilia drug development? Find out in DelveInsight's exclusive Pipeline Report—access it now! @ Hemophilia Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Hemophilia: Overview Pipeline Therapeutics Therapeutic Assessment Hemophilia– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Fitusiran: Alnylam Pharmaceuticals Mid Stage Products (Phase II) SerpinPC: Centessa Pharmaceuticals Drug profiles in the detailed report….. Early Stage Products (Phase I) Drug name: Company Name Preclinical and Discovery Stage Products Drug name: Company Name Inactive Products Hemophilia Key Companies Hemophilia Key Products Hemophilia- Unmet Needs Hemophilia- Market Drivers and Barriers Hemophilia- Future Perspectives and Conclusion Hemophilia Analyst Views Hemophilia Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
2 days ago
- Globe and Mail
Sleep Apnea Pipeline Outlook Report 2025: Key 10+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Sleep Apnea Pipeline Insight, 2025' report provides comprehensive insights about 10+ companies and 14+ pipeline drugs in Sleep Apnea pipeline landscape. It covers the Sleep Apnea pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sleep Apnea pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Sleep Apnea Treatment Landscape. Click here to read more @ Sleep Apnea Pipeline Outlook Key Takeaways from the Sleep Apnea Pipeline Report In July 2025, Mineralys Therapeutics Inc. announced a study is a randomized, double-blind (DB), placebo controlled, crossover study. A 4-week screening period is followed by two DB 4-week treatment periods separated by a 2-week washout period. Participants must be 18 to 75 years old with moderate to severe OSA, hypertension and meet all applicable eligibility criteria. Participants who are medically prescribed and deemed compliant with positive airway pressure (PAP) therapy for greater than or equal to (>=) 4 hours per night (Continuous PAP [CPAP], or automatic PAP [autoPAP]) and for at least 3 months prior to the study enrollment are eligible for the study. In July 2025, Eli Lilly and Company announced a study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization. The purpose of the studies is to evaluate the efficacy and safety of orforglipron in participants who have moderate-to-severe OSA and obesity or overweight. Study GZ01 will include participants who are unable or are unwilling to use PAP therapy. Study GZ02 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study. DelveInsight's Sleep Apnea pipeline report depicts a robust space with 10+ active players working to develop 14+ pipeline therapies for Sleep Apnea treatment. The leading Sleep Apnea Companies such as Apnimed, Incannex Healthcare, Fujian Shengdi Pharmaceutical, Eli Lilly and Company, RespireRx Phamaceuticals, Neurim Pharmaceuticals and others. Promising Sleep Apnea Pipeline Therapies such as Sivopixant, Acetazolamide, SAS0421a, VI-0521, Zonisamide, Sulthiame, AD128, BAY2586116 and others. Stay informed about the cutting-edge advancements in Sleep Apnea Treatments. Download for updates and be a part of the revolution in dermatology care @ Sleep Apnea Clinical Trials Assessment Sleep Apnea Emerging Drugs Profile AD109: Apnimed AD109 is an investigational oral therapy, a pill designed to target the underlying neuromuscular dysfunction in people living with mild, moderate, and severe obstructive sleep apnea (OSA). This novel treatment targets the hypoglossal motor nucleus (HMN) to increase signals in the upper airway dilator muscles during sleep to limit or prevent airway collapse. It is a potential first-in-class, novel, investigational combination dosed once daily at bedtime, designed to treat OSA patients across a broad spectrum of disease severity. AD109 combines company's novel selective antimuscarinic (aroxybutynin) with a selective norepinephrine reuptake inhibitor (atomoxetine). AD109 targets key neurological pathways in OSA that activate upper airway dilator muscles to maintain an open airway during sleep. AD109 has the potential to become a safe, effective, and convenient treatment for OSA, addressing some of the key limitations of current standard of care treatments that can be poorly tolerated (e.g., CPAP and oral devices) and/or invasive (e.g., surgery or implanted devices). Currently, the drug is in the Phase III stage of its development for the treatment of Obstructive Sleep Apnea. Dronabinol: RespireRx Phamaceuticals Dronabinol is a synthetic form of tetrahydrocannabinol (THC), the active compound in cannabis, primarily used to treat nausea, vomiting, and appetite loss. Research has shown potential for dronabinol in treating sleep apnea by stimulating the body's endocannabinoid receptors, which may help reduce apnea episodes and stabilize breathing during sleep. While not yet FDA-approved for sleep apnea, clinical studies suggest it could be beneficial in managing obstructive sleep apnea (OSA) symptoms. Currently, the drug is in the Phase II stage of its development for the treatment of Sleep Apnea. Gal 475: Neurim Pharmaceuticals GAL-475 is a novel therapeutic agent for the treatment of sleep apnea syndromes. In a series of in vitro and in vivo studies in various animal models it demonstrated improvements in sleep apnea indices with reductions in both the frequency and severity of events, without stimulating minute ventilation or disturbing sleep. Preclinical pharmacology studies with GAL-475 suggest that the compound acts predominantly as a peripheral chemoreception modulator, and indicate that the compound is effective in increasing respiratory drive to the upper airways and ameliorating obstructive apneas and their attendant sequelae in rodent models of obstructive apnea at relatively low plasma levels. The primary site of action for GAL-475 appears to be at the level of the carotid body, a peripheral polymodal chemosensory organ, located at the carotid bifurcation, responsible for sensing changes in partial pressures of O2, CO2 or pH, and activating the brainstem respiratory center to produce hyperventilation. Currently, the drug is in the Phase I stage of its development for the treatment of Sleep Apnea. The Sleep Apnea pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Sleep Apnea with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sleep Apnea Treatment. Sleep Apnea Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Sleep Apnea Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sleep Apnea market. Get a detailed analysis of the latest innovations in the Sleep Apnea pipeline. Explore DelveInsight's expert-driven report today! @ Sleep Apnea Unmet Needs Sleep Apnea Companies Apnimed, Incannex Healthcare, Fujian Shengdi Pharmaceutical, Eli Lilly and Company, RespireRx Phamaceuticals, Neurim Pharmaceuticals and others. Sleep Apnea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Sleep Apnea Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Discover the latest advancements in Sleep Apnea Treatment by visiting our website. Stay informed about how we're transforming the future of Dermatology @ Sleep Apnea Market Drivers and Barriers, and Future Perspectives Scope of the Sleep Apnea Pipeline Report Coverage- Global Sleep Apnea Companies- Apnimed, Incannex Healthcare, Fujian Shengdi Pharmaceutical, Eli Lilly and Company, RespireRx Phamaceuticals, Neurim Pharmaceuticals and others. Sleep Apnea Pipeline Therapies- Sivopixant, Acetazolamide, SAS0421a, VI-0521, Zonisamide, Sulthiame, AD128, BAY2586116 and others. Sleep Apnea Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Sleep Apnea Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Sleep Apnea Pipeline on our website @ Sleep Apnea Emerging Drugs and Companies Table of Contents Introduction Executive Summary Sleep Apnea: Overview Pipeline Therapeutics Therapeutic Assessment Sleep Apnea– DelveInsight's Analytical Perspective Late Stage Products (Phase III) AD109: Apnimed Drug profiles in the detailed report….. Mid Stage Products (Phase II) Dronabinol: RespireRx Phamaceuticals Drug profiles in the detailed report….. Early Stage Products (Phase I) Gal 475: Neurim Pharmaceuticals Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Sleep Apnea Key Companies Sleep Apnea Key Products Sleep Apnea- Unmet Needs Sleep Apnea- Market Drivers and Barriers Sleep Apnea- Future Perspectives and Conclusion Sleep Apnea Analyst Views Sleep Apnea Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
2 days ago
- Globe and Mail
JAK Inhibitors Pipeline Outlook Report 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, ' Janus Kinase (JAK) Inhibitor Pipeline Insight, 2025 ' report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Janus Kinase (JAK) Inhibitor pipeline landscape. It covers the JAK Inhibitors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the JAK Inhibitors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the JAK Inhibitors Treatment Landscape. Click here to read more @ JAK Inhibitors Pipeline Outlook Key Takeaways from the JAK Inhibitors Pipeline Report In June 2025, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announced a study has a total sample size of 78 participants. Of that 78, 52 participants will receive active treatment, and a total of 26 participants will receive placebo. Participants will receive 12 months of active treatment with abrocitinib, ritlecitinib, or placebo with up to 12 months of additional follow-up. During the study, participants will undergo frequent assessments of their insulin production, immunologic status, overall health and well-being and diabetes care. DelveInsight's JAK Inhibitors pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for JAK Inhibitors treatment. The leading JAK Inhibitors Companies such as Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis Biotherapeutics/Reistone Biopharma and others. Promising JAK Inhibitors Pipeline Therapies such as Abrocitinib 200 MG Oral Tablet, Ritlecitinib, GSK3196165 (Otilimab), Sarilumab, Ruxolitinib 0.15% Cream QD and others. Stay informed about the cutting-edge advancements in JAK Inhibitors Treatments. Download for updates and be a part of the revolution in Immunological and Autoimmune Disorders care @ JAK Inhibitors Clinical Trials Assessment JAK Inhibitors Emerging Drugs Profile Povorcitinib: Incyte Corporation Povorcitinib (INCB054707) is an oral small-molecule JAK1 inhibitor. The chemical structure for povorcitinib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as a Janus kinase inhibitor and anti-inflammatory agent. The drug is also being evaluated in Phase II clinical trials for Prurigo Nodularis, and others. Currently, the drug is in Phase III stage of its development for the treatment of Hidradenitis suppurativa, vitiligo. CPL409116: Celon Pharma CPL 409116 is the first in class dual JAK/ROCK inhibitor in clinical development and is designed to generate anti-inflammatory and anti-fibrotic effects in selected autoimmune diseases. CPL'116 was administered orally in single ascending doses in healthy volunteers in order to assess safety and pharmacokinetic parameters (PK). No adverse events associated with administration of the investigational drug were observed, and the trial met its primary endpoint. Currently the drug is in Phase II stage of development for autoimmune indications including in patients with rheumatoid arthritis with coexisting interstitial lung disease. ATI-2138: Aclaris Therapeutics ATI-2138 is an investigational oral covalent ITK/JAK3 inhibitor that is being developed as a potential therapeutic option across a variety of T cell-mediated diseases. ITK is a T cell receptor activated kinase involved in driving T cell effector functions while JAK3 is a non-receptor tyrosine kinase responsible for the signal transduction of common gamma receptor cytokines, IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. In blocking both T cell receptor function and cytokine signaling, ATI-2138 has potential utility in T cell driven diseases. ATI-2138 is currently in clinical development and its safety and efficacy has not been evaluated by regulatory authorities. SDC 1802: Sareum SDC-1802 is an investigational Sareum's TYK2/JAK1 preclinical development candidate molecule that demonstrates high selectivity for TYK2 and JAK1 kinases (particularly over related JAK2 and JAK3). SDC-1802 shows compelling efficacy in blocking cancer cell proliferation in cellular and disease models of T-cell acute lymphoblastic leukaemia (T-ALL) and B-cell lymphoma, the potential for once-daily oral dosing and a good early safety profile. Sareum is progressing SDC-1802 through preclinical development and pending satisfactory progress, into human clinical trials. SDC-1802 has the potential to act as a back-up molecule for these autoimmune indications. Currently, the drug is in Preclinical stage of its development for the treatment of cancer. The JAK Inhibitors pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of JAK Inhibitors with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for JAK Inhibitors Treatment. JAK Inhibitors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. JAK Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the JAK Inhibitors market. Get a detailed analysis of the latest innovations in the JAK Inhibitors pipeline. Explore DelveInsight's expert-driven report today! @ JAK Inhibitors Unmet Needs JAK Inhibitors Companies Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis Biotherapeutics/Reistone Biopharma and others. Janus Kinase (JAK) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical JAK Inhibitors Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Discover the latest advancements in JAK Inhibitors Treatment by visiting our website. Stay informed about how we're transforming the future of Immunological and Autoimmune Disorders @ JAK Inhibitors Market Drivers and Barriers, and Future Perspectives Scope of the JAK Inhibitors Pipeline Report Coverage- Global JAK Inhibitors Companies- Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis Biotherapeutics/Reistone Biopharma and others. JAK Inhibitors Pipeline Therapies- Abrocitinib 200 MG Oral Tablet, Ritlecitinib, GSK3196165 (Otilimab), Sarilumab, Ruxolitinib 0.15% Cream QD and others. JAK Inhibitors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination JAK Inhibitors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of JAK Inhibitors Pipeline on our website @ JAK Inhibitors Emerging Drugs and Companies Table of Contents Introduction Executive Summary Janus Kinase (JAK) Inhibitor: Overview Pipeline Therapeutics Therapeutic Assessment Janus Kinase (JAK) Inhibitor– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Povorcitinib: Incyte Corporation Drug profiles in the detailed report….. Mid Stage Products (Phase II) CPL409116: Celon Pharma Drug profiles in the detailed report….. Early Stage Products (Phase I) ATI-2138: Aclaris Therapeutics Drug profiles in the detailed report….. Preclinical and Discovery Stage Products SDC 1802: Sareum Drug profiles in the detailed report….. Inactive Products Janus Kinase (JAK) Inhibitor Key Companies Janus Kinase (JAK) Inhibitor Key Products Janus Kinase (JAK) Inhibitor- Unmet Needs Janus Kinase (JAK) Inhibitor- Market Drivers and Barriers Janus Kinase (JAK) Inhibitor- Future Perspectives and Conclusion Janus Kinase (JAK) Inhibitor Analyst Views Janus Kinase (JAK) Inhibitor Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
